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1ABSTRACT
S267F variant of sodium taurocholate cotransporting polypeptide
and its clinical association 
in Korean patients with chronic hepatitis B
Hye Won Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Sang Hoon Ahn)
Background: Sodium taurocholate cotransporting polypeptide (NTCP) was 
recently identified as a cellular receptor for hepatitis B virus (HBV). The 
substitution of serine residue at position 267 of NTCP with a phenylalanine 
residue (S267F) is an Asian-specific variation that hampers HBV entry in 
vitro. In this study, we aimed to evaluate the prevalence of S267F 
polymorphism in Korean patients with chronic hepatitis B (CHB) and its 
association with disease progression. We also investigated whether bile acids
affect the entry of HBV in vitro.
Methods: The effect of S267F variant on HBV infection was assessed using 
mutagenesis, transfection, virus inoculation and ELISA. For HBV preparation, 
HepAD38 cell line was used. The presence of S267F polymorphism was 
assessed in 1,200 patients with CHB and 176 individuals seronegative for 
hepatitis B surface antigen (HBsAg). Genomic DNA was extracted from 
whole blood and the S267F polymorphism was detected by polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP). The 
association between S267F mutation and its clinical association was also 
2analyzed.
Results: In vitro investigation using HepG2-NTCP cell line revealed that the 
S267F variant of NTCP reduced HBV infection and appears to compete with 
ursodeoxycholic acid for the NTCP receptor. The frequency of the S267F 
variant (genotype CT or TT) in Korean CHB patients and HBsAg-
seronegative individuals was 2.7% and 5.7% (P=0.031), respectively, and 
those who had S267F variant were less susceptible to HBV infection. The 
frequencies of the S267F variant in CHB, cirrhosis and hepatocellular 
carcinoma (HCC) patients were 3.3%, 0.9%, and 3.5%, respectively. S267F 
variant correlated significantly with a lower risk for cirrhosis (P=0.036),
while there was no significant correlation with the risk for HCC (P=0.887). 
Among the 32 patients who had S267F variant (genotype CT), 10 had not 
received antiviral treatment; their median HBV DNA level was 2.0 log10
IU/mL. In contrast, the median HBV DNA level of the 477 antiviral 
treatment-naïve patients with wild-type NTCP (genotype CC) was 2.9 log10
IU/mL (P=0.179).
Conclusion: We confirmed S267F variant of NTCP reduced HBV infection
in vitro. Also, the uptake of HBV and UDCA occurs competitively in
interaction with NTCP. The S267F variant of NTCP is clinically associated
with lower risk of HBV infection and cirrhosis development in Korean 
patients with CHB.
--------------------------------------------------------------------------------------
Key words: S267F variant, polymorphism, sodium taurocholate 
cotransporting polypeptide, hepatitis B
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I. INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis 
and hepatocellular carcinoma (HCC).1 Because progression of liver disease in 
patients with chronic hepatitis B (CHB) is fostered by active viral replication, 
a high level of HBV DNA, which indicates active virus replication, has been 
identified as an independent risk factor for development of cirrhosis and 
HCC.2-4 Thus, eradication or permanent suppression of HBV could
theoretically reduce the risk for liver disease progression.
HBV is an enveloped DNA virus with strict host-species and cell-type 
specificity.5 A complex combination of environmental, pathogenic and host 
genetic factors play a role in determining both susceptibility to HBV and the 
course of the infection. Among these factors, cellular entry is vital for 
4infection of target organs by enveloped viruses. HBV entry into and 
replication in hepatocytes are prerequisites for its pathogenesis. The former is 
mediated by the cellular receptor for the virus.6  
The viral membrane of the infectious HBV particle contains three 
envelope proteins: large (L, preS1+preS2+S), middle (M, preS2+S), and small 
(S only).7 The preS domain contributes to the viral life cycle at several steps, 
including attachment to the hepatocyte and budding of the virus at the 
endoplasmic reticulum.8 Particularly, the preS1 domain is associated with
viral attachment to the receptor.9 The S domain mediates HBV recruitment to 
the hepatocyte surface via heparin sulfate proteoglycans.10,11 All three proteins 
have identical C-terminal S domains, which contain the hepatitis B surface 
antigen (HBsAg). HBV infection is characterized by the presence of 
noninfectious subviral particles. The L protein has a conserved 77-amino acid 
N-terminal sequence in the pre-S1 domain. Myristoylation of this conserved 
sequence is essential for infectivity.12
Recently, sodium taurocholate cotransporting polypeptide (NTCP), known 
previously as solute carrier family 10 member 1 (SLC10A1), was identified as 
a functional species-specific HBV receptor.13,14 NTCP is specifically 
expressed at the basolateral membrane of hepatocytes and is encoded by the 
NTCP (SLC10A1) gene in humans. NTCP is involved in the essential reuptake 
of bile acids from the blood in the portal vein. NTCP is expressed on the 
hepatocyte surface and allowed for the bile acids to be resecretion into bile.15   
Genetic variations may influence the expression levels and the function of 
proteins. Single-nucleotide polymorphisms (SNPs), some of which are 
5specific to certain ethnicities, have been identified in the NTCP gene.16-19 The 
genetic variant I223T (c.668T>C) was identified in African-Americans at a 
frequency of 5.5%. S267F (c800C>T, p.Ser276Phe, and rs2296651) and 
I279T (c.836T>C) are Asian-specific SNPs, with allele frequencies of 7.5% 
and 0.5%, respectively. Patients with these variants also have lower bile acid 
transport activity. The S267F polymorphism is found in exon 4 of NTCP. Yan 
et al. conducted an in vitro investigation of the effect of the S267F 
polymorphism, which has been observed only in Asians, and at the highest 
frequency in East Asians.13 They found that this variant resulted in loss of 
HBV receptor function. However, the clinical implications of this finding
remain unknown. To date, no study of the effect of S267F variant on
susceptibility to HBV infection in Korean CHB patients has been conducted.
This study aimed to investigate the frequency of S267F variant of NTCP
in Korean CHB patients and the association between S267F mutation and the 
natural course of CHB.
6II. MATERIALS AND METHODS
1. HBV Preparation
HepAD38 cells20 were maintained in high-glucose Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco) with 10% fetal bovine serum (FBS, Gibco), 
penicillin, streptomycin (Welgene), and 1mg/ml doxycycline (Sigma-Aldrich). 
Medium was harvested every three or four days from HepAD38 cells 14-31 
days post-induction of HBV by depletion of doxycycline. Stored medium was
filtered through a 0.45-mm filter, precipitated with 40% (w/v) polyethylene 
glycol-8000 ([final]=6.2%, Sigma-Aldrich), mixed by end-over-end rotation 
overnight at 4°C. Viral precipitates were collected by centrifugation (4,500
rpm, 4°C, 1 h) and resuspended with fresh medium at ~1000-fold 
concentration. The HBV DNA was quantified by real time PCR.
2. Transient transfection 
HepG2-NTCP cells were transfected with wild-type NTCP plasmid or 
S267F-containing NTCP plasmid using TransIT-X2 Dynamic Delivery 
System (Mirus). Cells were maintained for 48 h after transfection and then 
they were inoculated with HBV (genotype D)20 in the presence of 4% PEG 
8000 at 37°C for 24 h. Cells were maintained in the presence of 2.5% DMSO 
and culture supernates were collected every 3 days. A commercial enzyme 
linked immunosorbent assay (ELISA) kit was used to measure secreted 
HBeAg levels in the sample medium. (Wantai Pharm Inc.)
73. HBV infection in the presence of ursodeoxycholic acid 
HepG2-NTCP cell line, which stably expresses NTCP, was kindly 
provided by Dr. Wang-Shick Ryu. HepG2-NTCP cells were maintained in 
high-glucose DMEM containing 10% FBS, penicillin and streptomycin 
(Welgene) at 37°C in a 5% CO2 environment. HepG2-NTCP cells were 
seeded in 48-well plates at a density of 7.5× 104 cells/well. HepG2-NTCP 
cells were infected with HBV in the presence of 4% PEG 8000 and 
ursodeoxycholic acid (UDCA) (0, 10, 30 and 90mM) at 37°C for 24 h. Cells 
were maintained in the presence of 2.5% DMSO and culture supernates were 
collected every 3 days. A commercial ELISA kit was used to measure 
secreted HBeAg levels in the sample medium (Wantai Pharm Inc.)
4. Patients
This study included 1,200 patients with CHB and 176 HBsAg-
seronegative individuals. All participants were recruited at Severance Hospital, 
Yonsei University College of Medicine, Seoul, Korea. Of the 1,200 patients 
with CHB, 333 were diagnosed with liver cirrhosis and 318 were diagnosed 
with HCC. Patients infected with other hepatitis viruses (with the exception of 
hepatitis C virus), autoimmune disorders, and other non-HBV diseases were 
excluded. Written informed consent was obtained from the patients or a 
responsible family member. This study was approved by the independent 
Institutional Review Board of Severance Hospital and conformed to the 
ethical guidelines of the 1975 Helsinki Declaration.
85. DNA purification and genotyping of S267F polymorphism
Genomic DNA was extracted from whole blood using the MiniBEST 
Universal Genomic DNA Extraction Kit Ver.5.0 (TaKaRa) according to the 
manufacturer’s instruction. The S267F polymorphism in NTCP was 
genotyped using the polymerase chain reaction–restriction fragment length 
polymorphism (PCR-RFLP) method. A 204-bp PCR fragment, including the 
S267F polymorphism in NTCP, was amplified using the following primer set:
5′-ATATGGCAATGAGGAGAAGC-3’ and 5′-
TTCCCTCTGAGTGTATGTGG-3′. PCR was performed in a 25-mL reaction 
containing 0.5 mL PfuTurbo DNA polymerase (2.5 U/mL), 2.5 mL 10x
reaction buffer (Agilent), 50-100ng genomic DNA, 0.5 mL dNTP (10 mM), 
0.5 mL (5 mM) of each primer, and up to 25 mL sterile double distilled water. 
The amplification was performed with the following conditions: first heated at 
95°C for 30 s and then amplified for 35 cycles by denaturation at 95°C for 
30 s, annealing at 55°C for 30 s, extension at 68°C for 30 s, and a final 
extension at 68°C for 5 min. The restriction fragments of S267F
polymorphism in NTCP were obtained using HphI (New England Biolabs) 
according to the manufacturer’s instruction. Digested fragments were 
electrophoresed on 3% agarose gels, stained with ethidium bromide, and 
visualized with UV transilluminator. The genotypes of the polymorphism in 
the individuals were determined according to the digestion pattern: genotype 
CC with a fragment of 204 bp, genotype CT with three fragments of 204, 120, 
and 84 bp, and genotype TT with two fragments of 120 and 84 bp (Fig. 1).
9Figure 1. NTCP genotype determination based on restriction digestion pattern. 
Wild-type NTCP (genotype CC) appeared as one band, S267F variant 
(genotype TT) showed two bands upon digestion. NTCP, sodium taurocholate 
cotransporting polypeptide.
6. Clinical evaluation
At baseline, routine blood chemistry parameters, serum HBV DNA level, 
and other serologic viral markers were assessed. HBsAg, HBeAg, and anti-
HBe were measured using ELISA (Abbott Laboratories, Chicago, IL). Serum 
HBV DNA levels were quantified using a commercially available real-time 
polymerase chain reaction (PCR) assay (COBAS AmpliPrep-COBAS TaqMan 
HBV test, Roche) with a linear detection range of 20–170,000,000 IU/mL. 
Serum alanine aminotransferase (ALT) levels were measured using standard 
laboratory procedures with the upper limit of normal set at 40 IU/L. 
If histologic information was not available, clinically diagnosed liver 
cirrhosis was defined as follows: (1) platelet count <100,000/μL and 
ultrasonographic findings suggestive of cirrhosis, including a blunted, nodular 
liver edge accompanied by splenomegaly (>12 cm); or (2) esophageal or 
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gastric varices.21 During follow-up, all patients underwent periodic 
surveillance with ultrasonography and laboratory workups, including 
determination of α-fetoprotein levels, at 3 or 6 month intervals.
7. Statistical analysis
Data are expressed as mean ± SD, median (range), or n (%), as appropriate. 
Differences among continuous variables were examined for statistical 
significance by Student’s t-test (or Mann-Whitney test, if appropriate). 
Categorical variables were analyzed by chi-square test (or Fisher’s exact test, 
if appropriate). The Cox proportional hazards model was used for multivariate 
analyses.
Hardy-Weinberg equilibrium (HWE) was tested using the Online 
Encyclopedia for Genetic Epidemiology HWE tool (OEGE).22 Genotype 
association was analyzed with Chi-square (X2) test. 
All statistical analyses were performed using the Statistical Package for 
the Social Sciences (SPSS version 20.0, Armonk, NY, USA) and SAS 
(version 9.2, SAS Inc., Cary, NC, USA). A value of P < 0.05 was considered 
to indicate statistical significance.
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III. RESULTS
1. Transient transfection of NTCP plasmid
To confirm the role of S267F mutation in HBV infection, HepG2-
NTCP cells were transfected with either wild-type NTCP or 
NTCP/S267F variant plasmid. We inoculated the transfected cells with 
HBV and measured secreted HBeAg as a reporter for HBV infection. 
Secreted HBeAg levels were about 2-fold lower in cells transfected 
with S267F-containing NTCP plasmid than those transfected with the 
wild-type NTCP plasmid (Fig. 2). This result indicates an association
between S267F variant of NTCP and reduced HBV infection.
           
Figure 2. Comparison of HBV uptake levels between wild-type and 
S267F NTCP. The secreted HBeAg levels were markedly reduced in 
the cells transfected with S267F-containing NTCP plasmid. HBV, 
hepatitis B virus; HBeAg, hepatitis B e antigen.
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2. Effects of ursodeoxycholic acid on hepatitis B virus infection
We investigated the changes in HBV entry upon UDCA treatment. UDCA 
(3α, 7β-dihydroxy-5β-cholanic acid), a dihydroxy bile acid, is one of the 
secondary bile acids.23 We hypothesized that the uptake of UDCA and HBV 
entry would occur competitively because both processes employ the same 
NTCP protein. Therefore, we designed the experiment to determine the effect 
on HBV infectivity by varying the amount of UDCA. As the concentration of 
UDCA increases (from 0 to 90 mM), we observed a decrease in secreted 
HBeAg (Fig. 3). This result suggests that HBV and UDCA compete for 
interaction with NTCP. 
Figure 3. The changes in HBV entry in the presence of UDCA. Secreted 
HBeAg decreased when the amount of UCDA increased. HBV, hepatitis B 
virus; HBeAg, hepatitis B e antigen; UDCA, ursodeoxycholic acid.
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3. Baseline characteristics
The baseline characteristics of the 1,376 study subjects are summarized in 
Table 1. In total, we analyzed 1,200 patients with CHB and 176 HBsAg-
seronegative individuals. For CHB patients, the mean age was 50.5 years, 
with more males than females (n = 803; 66.9%). Patients with CHB had lower  
platelet levels and higher AST and ALT levels than HBsAg-seronegative 
individuals. The mean HBV DNA level was 2.9 log10 IU/mL and 269 (22.4%) 
patients were positive for HBeAg. In total, 709 (59.1%) patients received 
antiviral treatment. In the CHB patients, the S267F polymorphism genotypes 
were distributed as follows: 1,168 (97.3%) patients were wild-type 
homozygote (CC) and 32 (2.7%) were heterozygote (CT).
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Table 1. Baseline characteristics of the study population
Variable
CHB 
(n=1,200)
HBsAg 
negative 
individuals
(n=176)
P value
Demographic 
Age, years 50.5 ± 11.7 47.8 ± 13.8 <0.001
Male gender 803 (66.9) 88 (50%) <0.001
Laboratory 
Platelet (103/mL) 92.0 ± 91.2 117.9 ± 104.7 0.001
Serum albumin (g/dL) 3.5 ± 0.7 3.6 ± 0.5 0.134
AST (IU/L) 122.0 ± 368.9 48.6 ± 53.8 0.043
ALT (IU/L) 91.8 ± 169.5 36.8 ± 43.4 0.002
HBV-related 
HBV DNA, log 10IU/mL 2.9 ± 2.1
HBeAg positivity 269 (22.4)
Antiviral therapy 709 (59.1)
Polymorphism-related 
S267F 0.031
CC 1,168 (97.3) 166 (94.3)
CT 32 (2.7) 9 (5.1)
TT 0 (0) 1 (0.6)
Variables are expressed as mean ± SD (range) or n (%). 
CHB, chronic hepatitis B; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; HBV, hepatitis B virus; HBeAg, HBV e antigen.
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4. Frequency of S267F variant in controls and patients with CHB
Genotype distribution analysis showed that the frequency of the S267F 
was in Hardy-Weinberg equilibrium. No departure from the Hardy-Weinberg 
distribution was observed for this genotype (P=0.640) in CHB or HBs-
seronegative individuals.
S267F polymorphism was associated with reduced infectivity in CHB 
patients compared with HBs-seronegative individuals (Table 2). The 
genotype distributions of S267F polymorphism differed significantly between
Korean CHB patients and HBsAg-seronegative individuals. The frequency of 
genotype CT or TT in CHB patients was lower than HBs-seronegative 
individuals (2.7% vs. 5.7%). Also, the risk of HBV infection was significantly 
lower in patients with genotype CT than those with genotype CC (odds ratio 
[OR] 0.455, 95% confidence interval [CI] 0.220-0.942, P=0.034) .
Table 2. Association of S267F polymorphism with chronic HBV infection
CHB
HBs-
seronegative 
individuals
OR 95% CI P value
S267F
CC 1168 (97.3) 166 (94.3) 1.000
CT 32 (2.7) 9 (5.1) 0.455 0.220-0.942 0.034
TT 0 (0) 1 (0.6)
Variables are expressed as means ± SD (range) or n (%). 
CHB, chronic hepatitis B; OR, odds ratio; 95% CI, 95% confidence interval.
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5. Association of S267F polymorphism with disease course of chronic 
HBV infection
The population was further stratified for a subgroup analysis, 
distinguishing CHB patients without cirrhosis or HCC (n=549) from CHB 
patients with cirrhosis (n=333) and CHB patients with HCC (n=318) (Table 
3). The S267F polymorphism was detected in 3.3% (n=18) of patients with 
CHB only, 0.9% (n=3) of patients with CHB and cirrhosis, and 3.5% (n=11) 
of patients with CHB and HCC. The frequency of genotype CT was higher in 
CHB only patients than in cirrhotic patients with CHB. As shown in Table 4, 
The presence of S267F variant correlated significantly with a lower risk of 
developing cirrhosis (OR 0.268, 95% CI 0.078-0.917, P=0.036). However, 
there was no significant difference in the risk of developing HCC in CHB 
patients (OR 0.946, 95% CI 0.441-2.029, P=0.887). Also, the S267F variant 
was associated with a decreased risk of developing HCC from cirrhosis (OR 
0.254, 95% CI 0.070-0.918, P=0.037).
Table 3. Genotype of NTCP in patients with CHB, with or without either 
cirrhosis or HCC
S267F
CHB only CHB + LC CHB + HCC
(n=549) (n=333) (n=318)
Genotype
CC 531 (96.7) 330 (99.1) 307 (96.5)
CT 18 (3.3) 3 (0.9) 11 (3.5)
Data are expressed as n (%)
CHB, chronic hepatitis B; LC, liver cirrhosis, HCC, hepatocellular carcinoma.
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Table 4. Association of S267F polymorphism with disease progression in 
patients with CHB infection
S267F
CHB vs. LC CHB vs. HCC LC vs. HCC
P
OR
(95%CI)
P
OR
(95%CI)
P
OR
(95%CI)
Genotype
CC 1.0 1.0 1.0
CT 0.036
0.268
(0.078-
0.917)
0.887
0.946
(0.441-
2.029)
0.037
0.254
(0.070-
0.918)
Data are expressed as n (%)
CHB, chronic hepatitis B; LC, liver cirrhosis, HCC, hepatocellular carcinoma; 
OR, odd ratio; 95% CI, confidence interval.
6. Correlation of S267F polymorphism with HBV DNA level in 
patients who did not receive antiviral therapy
The presence of S267F variant was associated with reduced HBV 
infection. Thus, we hypothesized that the S267F variant might decrease the 
spread of HBV-infected hepatocytes and result in low viral titers. HBV DNA 
levels of treatment-naïve patients with and without S267F variant were 
compared (Fig. 4). Among the 32 CT heterozygote patients, 10 (31.3%) were 
treatment-naïve, and these individuals had a median DNA level of 2.0 log10
IU/mL (range, 1.08-4.66 IU/mL). In comparison, the median DNA level of 
the 477 treatment-naïve CC homozygote patients was 2.9 log10 IU/mL (range, 
1.30-8.10, P=0.179). 
18
   
Figure 4. HBV DNA level in patients with and without S267F variant. The 
median HBV DNA level was higher in patients without S267F variant.
HBV, hepatitis B virus.
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IV. DISCUSSION
NTCP plays an important role in both the enterohepatic circulation of bile 
acids and in hepatocyte function.24 Until recently, NTCP has been known as a
bile acid transporter18,19 and this protein also participates in transporting 
steroid hormones, drugs (e.g., cyclosporine), and peptide ligand. Human 
NTCP consists of 349 amino acids with nine predicted transmembrane 
domains.25 To date, six SNPs have been identified in NTCP19 and some of 
these SNPs are found in specific ethnic backgrounds. Among them, the S267F 
polymorphism in exon 4 of NTCP has been identified only in Eastern Asians.6
NTCP was recently proposed to be a functional cell surface receptor for
HBV entry into hepatocytes.13,26 The region between amino acids 157 and 165 
is the most essential for HBV infection.27 Amino acids 84-87 of NTCP are
also considered important for HBV infection.9 Interestingly, HBV entry and 
bile acid transport share common molecular determinants on NTCP. Thus, 
genetic variation of NTCP could have effects on not only the HBV entry, but 
also bile acids uptake. Firstly, we have been questioned how the uptake of bile 
acids and HBV would occur.
To confirm this question, an in vitro experiment was performed using 
UDCA. UDCA (3α, 7β-dihydroxy-5β-cholanic acid), is a dihydroxy,    
secondary bile acid. Its role in lowering ALT levels in chronic liver diseases 
has been reported.28 In our study, HBV infection was inhibited in a dose-
dependent manner when the cells were inoculated with HBV and UDCA. This 
result suggests that HBV and UDCA employed NTCP competitively. This 
opens up new possibilities for the management of HBV infection using NTCP 
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substrates. However, the concentration of UDCA in the experiment (0-90 mM)
is different from the ones in real clinical settings. Standard doses of UDCA 
treatment is within the range of 12-15 mg/kg body weight.29 In other words,
the concentration of UDCA, when applied to patients, is relatively too high 
compared to when it is used in experiments. Thus, further studies are required 
regarding the influence of UDCA in the course of hepatitis B.
The frequency of Asian-specific S267F variant differs slightly according 
to ethnicity: 3.1-5.0% in Koreans, 7.4% in Chinese, 7.5% in Chinese-
Americans, and 9.2% in Vietnamese.6,17,19 In our study, the frequency of the 
S267F variant in HBsAg-seronegative individuals was 5.7%, consistent with 
the previous report. We also confirmed that HBV infection was inhibited in 
the presence of the S267F variant in vitro. We also sequenced the preS1 
domain of HBV from the S267F variant-containing samples to see whether 
the presence of S267F variant exerted a selective pressure that is strong 
enough to drive viral evolution in the preS1 domain. However, we could not 
observe any sequence variation, especially in the essential residues for NTCP 
binding (data are not shown).
So far, three studies have been reported regarding the association between
NTCP polymorphism and the clinical characteristics of CHB. We summarized 
the results of these studies including ours in Table 5. 
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Table 5. Summary of the previous studies on NTCP polymorphism
Authors Li et al.6 Peng et al.30 Hu et al.31 This Study
Group Chinese Han Chinese Han Taiwanese Korean
Study 
population
n=244 
(CHB patients)
n=76 
(HBV infection 
resolvers)
n=113 (healthy 
controls)
n=1,899
(CHB patients)
n=1,828 
(healthy 
individuals)
n=3,801 
(CHB patients)
n=3,801 
(HBsAg-
seronegative 
controls)
n=1,200 
(CHB 
patients)
n=176 
(HBsAg-
seronegative 
controls)
S267F is 
associated 
with
Increased HBV 
infection 
Decreased 
HBV infection 
Decreased 
HBV infection 
Decreased 
HBV 
infection 
Clinical 
significance
No significant 
association 
between S267F 
and cirrhosis, 
HCC
Lower risk of 
ACLF 
Lower risk of 
cirrhosis and 
HCC 
Lower risk 
of cirrhosis 
CHB, chronic hepatitis B; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; 
ACLF, acute-on-chronic liver failure.
All studies were performed for Asian patients. Taken together, patients with 
the S267F variant seem to be less susceptible to HBV infection. With the 
exception of the first study,6 the S267F variant in NTCP is associated with 
reduced HBV infection and subsequent disease course, including acute-on-
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chronic liver failure, cirrhosis and HCC. Only the first study6 presents 
conflicting data about susceptibility. However, the clinical significance this 
variant with cirrhosis or HCC requires additional study because various
factors in combination could affect disease progression.
Our results showed patients with the S267F variant were less susceptible 
to HBV infection. Patients with S267F variant also had a lower risk of 
developing cirrhosis. Cirrhosis develops as a result of inflammation and 
fibrosis in patients with CHB. Increased HBV DNA level is one of the most 
important risk factors for cirrhosis development.2 Since S267F variant is 
associated with lower HBV DNA level, the chance of cirrhosis development 
could be reduced in patients with S267F variant. However, we did not find
any significant, direct association between S267F variant and HCC 
development. Perhaps, carcinogenesis occurs from many different 
mechanisms including HBV infection, changes in the host immune system, 
and behavioral factors associated with HBV infection.32    
This is the first study to investigate S267F variant of NTCP in Korean 
patients with CHB. Therefore, the S267F variant seems to associate with the 
susceptibility to, and chronicity, of HBV infection in Asian population. 
However, whether the level of HBV viremia is critical for interference with 
bile acid transport remains unclear. Treatment-naïve patients were analyzed 
separately to confirm the correlation between the HBV DNA level and S267F 
variant. We hypothesized that patients with S267F would have lower HBV 
DNA levels than those without. Although the median HBV DNA level was 
slightly lower with the patients who had S267F variant, the difference was not 
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statistically significant. Notably, this result is difficult to interpret because the 
number of treatment-naïve patients with S267F variant was small.
This study has some limitations. First, the study population was 
heterogeneous. Second, only the S267F variant of SLC10A1 was genotyped.
Because other factors might be involved in HBV entry, the role of NTCP 
could have been overestimated until additional analysis is conducted. Third, 
the sample size varied between the groups, and only a small number of 
patients harbored the S267F variant. However, the overall prevalence of 
S267F variant was consistent with previous reports (Table 4). Finally, we 
tried immunofluorescence to detect HBcAg from the infected cells but failed. 
We also used HBeAg ELISA, instead of HBsAg ELISA, to confirm the 
degree of HBV infection. Such method agrees with the fact that HBsAg is not 
a reliable marker of productive HBV infection, especially at early time points,
as reported by Li et al.33 Future validation would likely enhance our 
understanding of the role of NTCP.
As resistance to the existing antiviral agents increased, new therapeutic 
agents is urgently needed. To date, Myrcludex B is an antiviral candidate
targeting NTCP,34 and this protein could be considered as a new therapeutic 
target for curing chronic HBV infection.
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V. CONCLUSION
   The S267F variant of NTCP is associated with lower levels of HBV 
infection in vitro. In addition, UDCA treatment inhibited HBV 
infection in a dose-dependent manner.
The frequency of the S267F variant (genotype CT or TT) was 2.7% and 
5.7% in Korean patients with CHB and HBsAg-seronegative individuals,
respectively. Patients who had the S267F variant of NTCP were less 
susceptible to HBV infection. The frequency of S267F variant was 3.3% in 
CHB patients, 0.9% in cirrhosis patients, and 3.5% in HCC patients. The 
S267F variant correlated significantly with a lower risk of cirrhosis
development. Further functional analysis of NTCP should increase our
understanding of HBV biology. 
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ABSTRACT (IN KOREAN)
국내 만성 B형간염 환자에서 B형간염 바이러스 세포 수용체인
NTCP의 S267F 변이와 임상적 연관성
<지도교수 안 상 훈>
연세대학교 대학원 의학과
이 혜 원
서론: Sodium taurocholate co-transporting polypeptide (NTCP)는 최근
B형간염 바이러스의 수용체로 밝혀졌다. NTCP 수용체의 267번 위치에
serine에서 phenylalanine로의 치환 (S267F 변이)은 아시아에서
특이적인 변이로 in vitro 실험에서 B형간염 바이러스의 감염을 방해하는
것으로 보고되었다. 본 연구에서는 국내 만성 B형간염 환자들에서
S267F 변이의 유병률을 살펴보고 만성 B형간염 질병 경과와의 연관성에
대해 알아보고자 한다. 또한, 담즙산이 B형간염 바이러스의 세포 내
감염에 영향을 주는지 in vitro 실험을 통해 확인하고자 한다.
방법: S267F 변이가 B형간염 감염에 미치는 영향을 보기 위해
mutagenesis, transfection, virus inoculation과 ELISA 방법을
이용하였다. B형간염 바이러스의 경우 HepAD38 세포주를 이용하여
virus induction, supernatant collection 및 concentration, real-time 
PCR을 통한 정량화 방법으로 준비하였다. 만성 B형간염 환자
1,200명과 B형간염 표면 항원 음성인 176명에 대하여 NTCP의 S267F 
변이를 조사하였다. 혈액으로부터 genomic DNA를 추출하였고, 중합효소
연쇄반응-제한 효소 절편 길이 다형성 (PCR-RFLP)을 이용하여 S267F 
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변이 여부를 검사하였다. 또한, S267F 변이와 임상적 연관성에 대해서도
함께 분석하였다.
결과: HepG2-NTCP cell line을 이용한 in vitro 실험결과 NTCP 267F 
변이가 B형간염 바이러스 감염에 음성적 효과 (negative effect)를
나타냈고, UDCA에 의해 용량 의존적으로 B형간염 바이러스 감염이
감소함을 확인하였다. NTCP의 267F 변이 (CT or TT 유전자형) 비율은
만성 B형간염 환자에서 2.7%, B형간염 표면 항원 음성인 군에서 5.7% 
였고 (P=0.031), S267F 변이가 있는 경우 B형간염 감염에 덜
민감하다는 것을 확인하였다. S267F 변이의 비율은 만성 B형간염
환자에서 3.3%, 간경화에서 0.9%, 간암 환자에서 3.5% 였다. 통계적
분석 결과 S267F 변이가 있는 경우 간경화 발생의 위험이 낮아졌고
(P=0.036), 반면 간암 발생과는 통계적 유의성을 보이지 않았다
(P=0.887). S267F 변이가 있는 32명의 환자 중 10명의 환자가 이전에
B형간염 관련 치료를 받은 과거력이 없었으며 이들의 B형간염 바이러스
DNA 중앙값은 2.0 log10 IU/mL 이었다. 그러나 이전 항바이러스
치료력이 없고 동시에 S267F 변이가 없는 (CC 유전자형) 477명의
환자들의 B형간염 바이러스 DNA 중앙값은 2.9 log10 IU/mL 
(P=0.179)이었다. 
결론: in vitro 실험을 통해 우리는 NTCP의 S267F 변이가 B형간염
바이러스의 감염을 감소시킴을 확인하였다. 또한 B형간염 바이러스와
UDCA의 세포 내 수용은 NTCP에 대하여 경쟁적으로 작용한다. 
NTCP의 267F 변이는 임상적으로 국내 만성 B형간염 환자들에서
B형간염 바이러스의 낮은 감염력 및 간경화 위험도와 관련이 있다.
-----------------------------------------------------------------------------------------------------
핵심되는 말: rs2296652, 유전적 다형성, sodium tahrocholate 
cotransporting polypeptide, B형간염
